Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
208 hedge funds and large institutions have $2.91B invested in Global Blood Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 89 increasing their positions, 53 reducing their positions, and 41 closing their positions.
84% more call options, than puts
Call options by funds: $58.9M | Put options by funds: $32.1M
68% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 53
7% less funds holding
Funds holding: 223 → 208 (-15)
7% less capital invested
Capital invested by funds: $3.13B → $2.91B (-$222M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
29% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36.9M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$25.4M |
| 3 |
BlackRock
New York
|
+$25.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21M |
| 5 |
AG
Artal Group
Luxembourg
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$95.5M |
| 2 |
LM
Luminus Management
Houston,
Texas
|
-$20.4M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$15.8M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$12.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.2M |
GBT Hedge Fund Activity: Q3 2019 in Review
208 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2019, worth a combined $2.91B — down 7.1% from $3.13B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of GBT and 29 opened new positions — a net loss of 12 holders — while 53 trimmed existing stakes and 89 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $36.9M. The largest seller was Fidelity Investments, cutting an estimated $95.5M.
- 208 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2019, down from 223 in Q2 2019.
- Funds reported $2.91B of Global Blood Therapeutics, Inc. stock for Q3 2019, down 7.1% quarter-over-quarter.
- 29 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2019 and 41 closed out, a net change of -12 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2019 was Point72 Asset Management, an estimated $36.9M added.
- The largest Global Blood Therapeutics, Inc. seller in Q3 2019 was Fidelity Investments, an estimated $95.5M sold.
Based on aggregated 13F filings for Q3 2019.